{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056427","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.005431+00:00","generated_at":"2026-06-28T09:31:39.775381+00:00","sec_items":["2.02","7.01","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TherapeuticsMD Q3 net product revenue $24.5M (+41% YoY); appoints Hugh O'Dowd CEO","bullets":["CEO Robert Finizio to become Vice Chair; President Hugh O'Dowd becomes CEO effective on or before Dec 31, 2021.","Q3 net product revenue $24.5M, up 41% YoY; ANNOVERA TRx 8,351 (+62.7% YoY).","Net loss $47.4M ($0.11/sh) vs $32.6M ($0.12/sh) in Q3 2020; includes $7.3M severance.","Cost savings plan to cut SG&A by $40M in 2022; additional ~$20M annualized from vitaCare divestiture.","Manufacturing issues: ANNOVERA batch failures; supplemental NDA PDUFA date Dec 12, 2021; revenue covenant risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056427","json":"https://secwatch.observer/filing/0001564590-21-056427.json","markdown":"https://secwatch.observer/filing/0001564590-21-056427.md","text":"https://secwatch.observer/filing/0001564590-21-056427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/txmd-8k_20211111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:31:39.775381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d3198aef6","claim":"Hugh O'Dowd was appointed as Director at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. O’Dowd will also be appointed to the Company’s Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a7d2c80f75","claim":"Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. Hugh O’Dowd, the Company’s current President, will succeed Mr. Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, as the Company’s Chief Executive Officer effective on or before December 31, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b6c8f2fd85","claim":"Robert G. Finizio was appointed as Vice Chair of the Board of Directors at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice Chair of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}